Clinical Trials
36 trialsSTIM 2
University Hospital, Bordeaux
Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study
Ohio State University Comprehensive Cancer Center
BMT
Massachusetts General Hospital
Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia
American University of Beirut Medical Center
A Mobile Intervention (txt4TKI) for the Improvement of Tyrosine Kinase Inhibitor Management in Patients With Chronic Myeloid Leukemia
Thomas Jefferson University
MargheRITA
Advice Pharma Group srl
The EMPATHY Pilot Study
Northwestern University
DISCO Application for the Improvement of Financial Outcomes in Patients With Hematologic Cancer
Barbara Ann Karmanos Cancer Institute
A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors
University of California, San Francisco
Mini-allo
Scripps Health
Unrelated Donor Stem Cell Transplantation
Scripps Health
Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008
Pfizer
CAR-LMC
Centre Hospitalier Universitaire de Besancon
Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate
M.D. Anderson Cancer Center
Cognitive Behavioral Intervention for Targeted Therapy Fatigue (CBT-TTF) Intervention
H. Lee Moffitt Cancer Center and Research Institute
IM-TMI
University of Illinois at Chicago
Unrelated Umbilical Cord Blood (UBC)Transplantation
West Virginia University
Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies
Dartmouth-Hitchcock Medical Center
Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation
National Institutes of Health Clinical Center (CC)
Effects of a Digital Patient Platform (CMyLife) for Patients With Chronic Myeloid Leukemia (CML) on Information Provision, Patient Empowerment, Medication Compliance, Guideline Adherence and Quality of Life
Radboud University Medical Center
TAR
Baylor College of Medicine
Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy
Nanfang Hospital, Southern Medical University
Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia
National Institutes of Health Clinical Center (CC)
Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC])
Ann & Robert H Lurie Children's Hospital of Chicago
Impact of a Pharmaceutical Care Model in the Management of Chronic Myeloid Leukemia Patients
UCSI University
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
University of Illinois at Chicago
Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia
Masonic Cancer Center, University of Minnesota
TAKE-IT
Rabin Medical Center
An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
King Faisal Specialist Hospital & Research Center
Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Natural Killer Index From Hematopoietic Stem Cell Graft
Nantes University Hospital
Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal Tumors
Memorial Sloan Kettering Cancer Center
STIM
University Hospital, Bordeaux
Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies
Stanford University
Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients
M.D. Anderson Cancer Center
GLIFERTI
Assistance Publique - Hôpitaux de Paris